Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02153099 · ClinicalTrials.gov registry record · Phase 1
Safety, Tolerability and Pharmacokinetics of Escalating Single Doses of ENV8058 (TAK-058) in Healthy Participants
A Phase 1 study, sponsored by Takeda.
- Completed
- Registry status
- Phase 1
- Development phase
- 48
- Enrollment target
NCT02153099 is a Phase 1 study that has completed, run by Takeda. The registered enrollment target is 48 participants.
The verdict
NCT02153099, a Phase 1 study, has completed, sponsored by Takeda.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 48 participants
- Enrollment target
Study Summary
The purpose of this study is to characterize the safety and tolerability profile of escalating dose levels of ENV8058 (TAK-058) solution when administered as a single oral dose in healthy adults.
Interventions
- DRUG Placebo
- DRUG TAK-058 (ENV8058)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 48 participants |
| Start Date | 2014-06 |
| Est. Completion | 2014-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02153099
The ClinicalTrials.gov registry entry for NCT02153099 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 48 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Takeda, which has 408 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02153099 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02153099 about?
NCT02153099 is a clinical study titled "Safety, Tolerability and Pharmacokinetics of Escalating Single Doses of ENV8058 (TAK-058) in Healthy Participants". The purpose of this study is to characterize the safety and tolerability profile of escalating dose levels of ENV8058 (TAK-058) solution when administered as a single oral dose in healthy adults.
What is the current status of trial NCT02153099?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 48 participants. The study started on 2014-06. Estimated completion is 2014-11.
What interventions are being tested in trial NCT02153099?
The interventions under investigation include: Placebo (DRUG), TAK-058 (ENV8058) (DRUG).
Who is sponsoring clinical trial NCT02153099?
This trial is sponsored by Takeda, which has 408 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.